GENE ONLINE|News &
Opinion
Blog

AbbVie
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Dutch Pharmaceutical Watchdog Organization Sues Abbvie over Humira Pricing
2023-02-22
AbbVie and Genmab’s Joint Cancer Treatment Receives EMA Validation
2022-10-28
AbbVie Buys DJS Antibodies For $255 Million To Beef Up Immunology Portfolio
2022-10-21
New Data Shows the Long Term Effectiveness of AbbVie’s Psoriatic Arthritis Treatment
2022-09-12
Sosei Heptares and Abbvie Partner in Potential $1.2 Billion Neurological Disease Deal
2022-08-02
AbbVie Scores First FDA Thumbs Up for Crohn’s Disease
2022-06-20
AbbVie & Cugene Join Forces to Tackle Autoimmune Diseases
2022-05-17
AbbVie’s Big Moves; Expanding with One Company, Cutting Ties with Another
2022-04-21
Compensating for OxyContin: The Harm from Pharma
2022-04-12
How Did the Russian Invasion of Ukraine Affect Global Biopharma?
2022-03-16
Abbvie Acquires Neuroscience Company Syndesi for $1 Billion
2022-03-02
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
2022-02-16
First Generic for Dry-eye Gets U.S. FDA Nod
2022-02-04
AbbVie Strikes Gene Therapy Pact with REGENXBIO to Tackle Eye Diseases
2021-09-14
1 2
LATEST
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scroll to Top